Search

AF solution

Chevron
Colorectal Cancer Organoid1_main
Cancer Organoid

Colorectal Cancer Organoid

Colorectal Cancer Organoid1_main

  • hCRC organoids exhibit a three-dimensional structure and cellular composition similar to colorectal cancer tissue.
  • They express proteins such as CK7, CK20, b-catenin, and CDX2, mirroring the characteristics of colorectal cancer tissue.
  • These organoids are highly valuable for analyzing genetic mutations in colorectal cancer and evaluating the efficacy of different chemotherapy treatments.

Organism
Product Type
Organoid
Tissue
Colon
Disease
Colorectal cancer

Applications

Oncology

The oncology drug efficacy evaluation platform is based on patient-derived organoids(PDOs).
This platform allows for the assessment of the efficacy of oncology agents and immunotherapeutics by utilizing a co-culture system with immune cells from the tumor microenvironment.

Immuno-Oncology

This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.

Tumor Microenvironment

CAFs promote cancer invasion and metastasis, potentially inducing resistance to anticancer drugs.
Considering these functions of CAFs is crucial for accurately assessing the efficacy of anticancer drugs and developing strategies to address these challenges.

Cancer Vaccine

Lead the future of treatment with our innovative cancer vaccine and mRNA therapy platform! Discover advanced solutions that provide better health and hope through our cutting-edge technology and scientific approach

Table of Contents

Cellular and structural similarity

Our colorectal cancer organoids accurately replicate patient tumors by expressing key markers CDX2, β-catenin, and CK20, underscoring their fidelity for cancer research and personalized treatment development.
This molecular mimicry enables a profound understanding of colorectal cancer’s pathology and offers a promising avenue for therapeutic innovations.

Colorectal cancer organoid

H&E
CDX2
β-catenin
CK20

Cancer tissue

Cancer organoid

Cancer organoid

Immunofluorescent staining with a proliferation marker (Ki-67), an epithelial marker (ECAD) and mature intestinal markers (DEFA5, OLFM4, MUC13, and KRT20).

Genetic mutation 

Unlock the essence of precision in cancer treatment with our colorectal cancer organoids, mirroring the  genetic markers of colorectal cancer.
Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing.
Dive into a new era of oncology, where your individuality guides our innovation.

Top mutated genes

Oncoplot of the top 26 most frequently mutated genes in 22 cases.

Colorectal cancer mutation PPI Network

Exploring genetic links in colorectal cancer crganoids: We analyze genetic correlations using a database of mutant proteins and their interactions to uncover critical insights into colorectal cancer.

Microsatellite instable

Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses.
Transform the standard with us—where your medication’s potential is as unique as you are.

Tissue

Normal

Cancer

BAT25
MSI (+)
LOH:
Uninformative
BAT26
MSI (+)
LOH:
Uninformative
D2S123
MSI (-)
LOH:
(-)
D5S346
MSI (+)
LOH:
(-)
D17S250
MSI (+)
LOH:
(-)

Organoid

Normal

Cancer

BAT25
MSI (+)
LOH:
Uninformative
BAT26
MSI (+)
LOH:
Uninformative
D2S123
MSI (-)
LOH:
(-)
D5S346
MSI (+)
LOH:
(+) L=0.312
D17S250
MSI (+)
LOH:
(-)

Drug response

Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses.
Transform the standard with us—where your medication’s potential is as unique as you are.

5-FU

Ctr
0.04μM
0.48μM
7.8μM
125μM
500μM

Oxaliplatin

Ctr
0.12μM
0.32μM
0.8μM
20μM
100μM

Irinotecan

Ctr
0.12μM
0.32μM
0.8μM
20μM
100μM

Oxaliplatin

Irinotecan

5-FU

Drug responses of patient-derived colorectal cancer organoids.
Dose-response curves generated from patient-derived colorectal cancer organoid lines treated with oxaliplatin, Irinotecan and 5-FU.
These figures demonstrate the percent of cell viability measured.

Organoid viability test CellTiterGlo vs WST

Important Details

  • Validity: Until September 30th, 23:59 German time.
  • Applicability: One experiment per indication (Oncology, Skin & Cosmetics, Organoids).
  • Flexibility: Use the coupon unlimited times until the event ends.
  • Conditions: Applies when proceeding with a contract.

Log in to MyLab and

download your gift voucher from the ‘Vouchers’ menu!

Thank you for your continued trust and partnership.
We look forward to serving you with excellence.